Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.245    0.025 (2.05%)
Bid:
1.14
Ask:
1.35
Spread: 0.21 (18.421%)
Market Cap: £28.62m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Director/PDMR Shareholding

12 Sep 2019 15:19

RNS Number : 1765M
Provexis PLC
12 September 2019
 

12 September 2019

 

Provexis plc

 

("Provexis" or the "Company")

 

Director / PDMR notification

 

 

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.

 

Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Ian Ford (Director and PDMR) - shares acquired on behalf of Mr Ford's children (under the age of 18) who are persons closely associated with Mr Ford

 

2

 

Reason for the notification

a)

 

Position/status

 

See 1a) above

 

b)

 

Initial notification

/ Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

PROVEXIS PLC

b)

 

LEI

 

21380042E3Y3N9VZ6N48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 0.1p each

 

 

 

ISIN: GB00B0923P27

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

 

 

 

 Price(s)

Volume(s)

0.33 pence

and

0.345 pence

2,500,000

 

2,500,000

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

5,000,000 shares

 

Average price of 0.338 pence per share

 

e)

 

Date of the transaction

 

12 September 2019

f)

 

Place of the transaction

 

London Stock Exchange, AIM Market

 

 

For further information please contact:

 

Provexis plc

Dawson Buck, Chairman

Ian Ford, CEO & CFO

 

Tel: 07490 391888

enquiries@provexis.com

Allenby Capital Limited

Nick Naylor / Liz Kirchner

Tel: 020 3328 5656

 

 

 

Notes for editors

 

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

 

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

 

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

 

For further information, please visit www.provexis.com and www.fruitflowplus.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGGUQGBUPBGCP
Date   Source Headline
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.